-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)
StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)
Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday. The brokerage set a "buy" rating on the stock.
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research report on Tuesday, July 5th.
Get Trinity Biotech alerts:Trinity Biotech Trading Down 5.1 %
Shares of TRIB opened at $1.16 on Friday. The stock has a market capitalization of $31.16 million, a P/E ratio of -2.27 and a beta of 1.33. The firm's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.22. Trinity Biotech has a 12 month low of $0.86 and a 12 month high of $3.05.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last issued its quarterly earnings results on Thursday, June 30th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $18.78 million for the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative return on equity of 347.92%.Hedge Funds Weigh In On Trinity Biotech
Several large investors have recently added to or reduced their stakes in TRIB. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Highbridge Capital Management LLC purchased a new stake in Trinity Biotech in the 1st quarter valued at about $1,221,000. Institutional investors own 27.11% of the company's stock.
Trinity Biotech Company Profile
(Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday. The brokerage set a "buy" rating on the stock.
斯托克新聞網的投資分析師在週五發佈給投資者的一份研究報告中對利邦生物科技(納斯達克：TRIB-GET評級)的股票進行了報道。該經紀公司對該股設定了“買入”評級。
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research report on Tuesday, July 5th.
另外，華爾街在7月5日星期二的一份研究報告中將利邦生物科技的股票評級從“c-”下調至“d”。
Trinity Biotech Trading Down 5.1 %
利邦生物科技股價下跌5.1%
Shares of TRIB opened at $1.16 on Friday. The stock has a market capitalization of $31.16 million, a P/E ratio of -2.27 and a beta of 1.33. The firm's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.22. Trinity Biotech has a 12 month low of $0.86 and a 12 month high of $3.05.
Trib的股票週五開盤報1.16美元。該股市值為3,116萬美元，市盈率為-2.27，貝塔係數為1.33。該公司的50日簡單移動均線切入位為1.35美元，200日簡單移動均線切入位為1.22美元。利邦生物科技的12個月低點為0.86美元，12個月高位為3.05美元。
Hedge Funds Weigh In On Trinity Biotech
對衝基金入股利邦生物科技
Several large investors have recently added to or reduced their stakes in TRIB. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Highbridge Capital Management LLC purchased a new stake in Trinity Biotech in the 1st quarter valued at about $1,221,000. Institutional investors own 27.11% of the company's stock.
幾家大型投資者最近增持或減持了Trib的股份。Atria Wealth Solutions Inc.在第一季度購買了利邦生物科技的一個新頭寸，價值約為27,000美元。Virtu Financial LLC在第一季度購買了利邦生物科技的一個新頭寸，價值約為4萬美元。懷特福德資本管理公司在第四季度購買了利邦生物科技的一個新頭寸，價值約5萬美元。Envestnet Asset Management Inc.在第四季度購買了利邦生物科技的一個新頭寸，價值約15.9萬美元。最後，Highbridge Capital Management LLC在第一季度收購了利邦生物科技的新股份，價值約1221,000美元。機構投資者持有該公司27.11%的股份。
Trinity Biotech Company Profile
利邦生物科技公司簡介
(Get Rating)
(獲取評級)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
利邦生物技術公司為美洲、非洲、亞洲和歐洲的診斷市場的臨牀實驗室和護理點(POC)細分市場收購、開發、製造和營銷醫療診斷產品。該公司提供臨牀實驗室產品，包括診斷測試和儀器，用於檢測傳染病，如萊姆病；由梅毒和皰疹組成的性傳播疾病；SARS-CoV-2；以及愛潑斯坦巴爾病毒、麻疹、腮腺炎、弓形體病、鉅細胞病毒、風疹、水痘和其他病毒病原體，以及用於監測和診斷糖尿病並識別有糖尿病風險的人的血紅蛋白A1c體外診斷測試的產品。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免費獲取StockNews.com關於利邦生物科技的研究報告(Trib)
- 耐克股票會被超賣，但仍被高估嗎？
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎？
- 皇家加勒比的寬帶合作能否推動收入增長？
- 芯片設備製造商Entigis很有潛力，但它現在可以買下嗎？
- DocuSign在報告收益時有重要的問題需要解決
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《利邦生物科技日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對利邦生物科技和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧